SAB BIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

SAB BIO (Nasdaq: SABS), a clinical-stage biopharma developing fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes and other autoimmune diseases, will participate in two September 2026 investor events: Citi’s Biopharma Back to School Conference and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York.

Argus Sep 1 session

-0.27% close to close Open Argus

Details

News Market Reaction – SABS

On Sep 1, the day this news came out, SABS closed 0.27% below the previous close.

Data tracked by StockTitan Argus for the Sep 1 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in upcoming investor conferences in September:

Citi Biopharma Back to School Conference
Date: September 10, 2026
Time: 11:20 - 11:55 a.m. ET
Format: Fireside Chat
Presenter: Samuel J. Reich, Chief Executive Officer
Location: New York, NY

Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 14, 2026
Format: One-on-one meetings
Location: New York, NY

SAB BIO management will be available for one-on-one meetings during the conferences. Interested parties should contact their conference representative to arrange a meeting. To access replay webcasts of investor events, please visit the Investors & Media section of SAB BIO’s website at www.sab.bio.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

CONTACTS

Investor Relations:
Christine Ryan
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will SAB BIO (SABS) present at the Citi Biopharma Back to School Conference in 2026?

SAB BIO will participate in the Citi Biopharma Back to School Conference on September 10, 2026, from 11:20 to 11:55 a.m. ET. According to SAB BIO, the format is a fireside chat presented by CEO Samuel J. Reich in New York.

What is SAB BIO’s schedule at the Morgan Stanley 24th Annual Global Healthcare Conference 2026?

SAB BIO will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026 in New York. According to SAB BIO, the company will participate in one-on-one investor meetings rather than a public presentation during this conference.

How can investors arrange one-on-one meetings with SAB BIO (Nasdaq: SABS) during the September 2026 conferences?

Investors can request one-on-one meetings with SAB BIO management through their respective conference representative. According to SAB BIO, management will be available for individual meetings at both the Citi Biopharma Back to School and Morgan Stanley Global Healthcare conferences in New York.

How can investors access SAB BIO’s investor event webcasts and replays for SABS?

Investors can access replay webcasts of SAB BIO investor events via the Investors & Media section of the company’s website at www.sab.bio. According to SAB BIO, this portal hosts recordings from prior investor presentations and conferences.